Mifepristone (RU486) Induces Polycystic Ovarian Syndrome in Female Wistar Rats with Features Analogous to Humans


Affiliations

  • University of Ilorin, Reproductive and Developmental Biochemistry Research Laboratory, Department of Biochemistry, Ilorin, Nigeria
  • University of Ilorin, Department of Physiology, Ilorin, Nigeria
  • University of Ilorin, Department of Pathology, Ilorin, Nigeria

Abstract

Numerous inducers of polycystic ovarian syndrome (PCOS) at different doses have been proposed in several experimental animals but there is no consensus on an appropriate dose(s) that should ideally reproduce the key biochemical and clinical features of PCOS similar to those of humans. Therefore, this study was aimed at investigating an appropriate dose(s) for the induction of PCOS in female Wistar rats. Twenty-four female albino rats (190.00 ± 13.00 g) with 4-5 days of estrus cyclicity were completely randomized into 4 groups (A - D) of six animals each. Animals in group A (control) were subcutaneously administered 0.2 ml of pure olive oil, while those in groups B, C and D were subcutaneously administered same volume corresponding to 5.0, 7.5 and 10.0 mg of mifepristone in olive oil for 9 days starting from the day of estrus (Day 1). The estrus cycle, serum testosterone (T), estradiol (E), prolactin (Pr), follicle-stimulating hormone (FSH), luteinizing hormone (LH), progesterone (P), insulin (Is), weight of the animals, fasting blood glucose (FBS) and ovarian morphology were monitored/evaluated/examined. The 5.0 mg of mifepristone extended the estrus stage for four days, increased (p<0.05) the levels of serum E, P, Pr, FSH, T, triacylglycerides (TAG), and total cholesterol (TC) as well as decreased the concentrations of LH and high density lipoprotein-cholesterol (HDL-C). There was no significant difference (p<0.05) in the Is concentration, animal body weights and FBS at day 10 in rats administered 5.0 mg of mifepristone. The 7.5 mg of mifepristone produced irregular estrus cycle, increased Pr, TAG, T, and TC concentrations and FBS whereas it decreased E, P, HDL-C, and LH. The Is, FSH and body weights of the animals were not significantly altered at 7.5 mg of mifepristone. The 10.0 mg of mifepristone produced irregular estrus cycle, increased the levels of E, TAG, Is, LH, T as well as decreased the levels of P and HDL-C. The levels of Pr, FSH, TC, body weights and FBS were not significantly altered at this dose. There was no ovarian follicular growth and atresia in the 5.0 and 7.5 mg mifepristone-treated rats whereas the 10 mg of mifepristone produced these histopathological features. Overall, the study concluded that subcutaneous administration of mifepristone (RU486) induces polycystic ovarian syndrome in rats through deprivation of progesterone with the 10 mg producing majority of the key biochemical and clinical features associated with PCOS in humans. The study, therefore, recommends the subcutaneous administration of mifepristone (RU486) on daily basis for 9 days as a good model for inducing PCOS in animals.

Keywords

PCOS, Mifepristone, Biochemical Features, Ovarian Morphology, Estrus Cyclicity.

Subject Discipline

Pharmacy and Pharmacology

Full Text:

References

Abbott DH, Dumesic DA, Franks S. (2002) Developmental origin of polycystic ovary syndrome- a hypothesis. J Endocrinol.. 174: 1-5.

Abbott DH, Barnett DK, Bruns CM, Dumesic DA. (2005) Androgen excess fetal programming of female reproduction: a developmental aetiology for polycystic ovary syndrome? Human Reprod.. 11: 357-374.

Baird DT. (2000) Mode of action of medical methods of abortion. J Am Med Womens Assoc. 55: 121-126.

Baravalle C, Salvetti, NR, Mira GA, Pezzone N, Ortega HH. (2006) Microscopic characterization of follicular structures in letrozole-induced polycystic ovarian syndrome in the rat. Arch Med Res. 27: 830-839.

Baulieu EE. (1991) The antisteroid RU486: its cellular and molecular mode of action. Tr Endocrinol Metab. 2: 233-239.

Brawer JR, Munoz M, Farookhi R. (1986) Development of the polycystic ovarian condition (PCO) in the estradiol valerate-treated rat. Biol Reprod.35: 647-655.

Conway GS, Jacobs HS, Holly JM, Wass JA. (1990) Effects of luteinizing hormone, insulin, insulin-like growth factorI and insulin-like growth factor small binding protein 1 in the polycystic ovary syndrome. Clin Endocrinol. (Oxford) 33:5 93-603.

Dabadghao P, Roberts BJ, Wang J, Davis MJ, Norman RJ. (2007) Glucose tolerance abnormalities in Australian women with polycystic ovary syndrome. Med J Australia 187: 328-331.

De Leo V, Lanzetta D, D’antona D, Marca A, Morgante G. (1998) Hormonal effects of flutamide in young women with polycystic ovary syndrome. J Clin Endocrinol Metab. 83:99-102.

Dipankar BM, Kumar S, Satinath M, Mamata P. (2005) Clinical correlation with biochemical status in polycystic ovary syndrome. J Obstet Gynec India 55: 67-71.

Dorrington JH, Gore-Langton RE. (1982) Antigonadal action of prolactin: further studies on the mechanism of inhibition of follicle-stimulating hormone-induced aromatase activity in rat granulosa cell cultures. Endocrinology 110:1701-1707.

Drury RAB, Wallington EA. (1980) Carlton’s Histological Techniques, ed 5, London: Oxford University Press, pp 344-345.

Dunaif A, Graf M, Mandeli J, Laumas V, Dobrjansky A. (1987) Characterization of groups of hyperandrogenic women with Acanthosis nigricans, impaired glucose tolerance, and/or hyperinsulinemia. J Clin Endocrinol Metab 65: 499-507.

Dunaif A, Segal KR, Futterweit W, Dobrjansky A. (1989) Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome. Diabetes 38: 1165-1174.

Fitzgerald P, Dinan TG. (2008) Prolactin and dopamine: What is the connection? A review. J Psychopharmacol 22: 12-19.

Franks S. (2005) Diagnosis of polycystic ovarian syndrome in defense of Rotterdam Criteria. J Clin Endocrinol Metab. 2: 2536-2538.

Franks S. (2012) Animal models and the developmental origins of polycystic ovary syndrome: increasing evidence for the role of androgens in programming reproductive and metabolic dysfunction. Endocrinology 153: 2536-2538.

Friedewald WT, Levy RI, Fredrickson DS. (1972) Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge Clin Chem. 18: 499-502.

Goldenberg N, Glueck C. (2008) Medical therapy in women with polycystic ovary syndrome before and during pregnancy and lactation. Minerva Ginecol. 60: 63-75.

Goldstein DP, Kosasa T. (1975). The subunit radioimmunoassay for luteinizing hormone clinical application. Gynecology 6: 45-84.

Goodarzi MO, Dumesic DA, Chazenbalk G, Azziz R. (2011) Polycystic ovary syndrome: etiology, pathogenesis and diagnosis. Nature Rev Endocrinol. 7: 219-231.

Hillier SG. (1990) Ovarian manipulation with pure gonadotropins. J Endocrinol. 127: 1-4.

Holte J, Bergh T, Berne C, Lithell H. (1994) Serum lipoprotein lipid profile in women with the polycystic ovary syndrome: relation to anthropometric, endocrine and metabolic variables. Clin Endocrinol. (Oxford) 41: 463-471.

Iwamasa J, Shibata S, Tanaka N, Matsuura K, Okamura H. (1992) The relationship between ovarian progesterone and proteolytic enzyme activity during ovulation in the gonadotropin-treated immature rat. Biol Reprod. 46: 308-313.

Jonard S, Dewailly D. (2004) Follicular excess in polycystic ovaries, due to intra ovarian hyperandrogenism may be the main culprit for follicular arrest. Human Reprod Update 10: 107-117.

Kafali H, Iriadam M, Ozardali I, Demir N. (2004) Letrozole induced polycystic ovaries in the rat: a new rat model for cystic ovarian disease. Arch Med Res. 35: 103-108.

Kalison B, Warshaw ML, Gibori G. (1985) Contrasting effects of prolactin on luteal and follicular steroidogenesis. J Endocrinol. 104: 241-250.

Kumar TR, Wang Y, Lu N, Matzuk MM. (1997) Follicle stimulating hormone is required for ovarian follicle maturation but not male fertility. Nature Gen. 15: 201-204.

Lakhani K, Yang W, Dooley A, El-Mahdi E, Sundaresan M, McLellan S, Bruckdorfer R, Leonard A, Seifalian A, Hardiman P. (2006) Aortic function is compromised in a rat model of polycystic ovary syndrome. Human Reprod. 21: 651-656.

Legro RS, Kunselman AR, Dunaif A. (2001) Prevalence and predictors of dyslipidemia in women with polycystic ovary syndrome. Am J Med. 111: 607-613.

Lobo RA, Carmina E. (2000) The importance of diagnosing the polycystic ovary syndrome. Ann Int Med. 132: 989-993.

Morales AJ, Laughlin GA, Butzow T, Maheshwari H, Baumann G, Yen SS. (1996) Insulin, somatotropic, and luteinizing hormone axes in lean and obese women with polycystic ovary syndrome: common and distinct features. J Clin Endocrinol Metab. 81: 2854-2864.

Padmanabhan V, Veiga-Lopez A. (2013) Sheep models of polycystic ovary syndrome phenotype. Mol Cell Endocrinol. 373: 8-20.

Pagan YL, Srouji SS, Jimenez Y, Emerson A, Gill S, Hall JE. (2006) Inverse relationship between luteinizing hormone and body mass index in polycystic ovarian syndrome: investigation of hypothalamic and pituitary contributions. J Clin Endocrinol Metab. 91:1309-1316.

Pasquali R, Stener-Victorin E, Yildiz BO, Duleba AJ, Hoeger K, Mason H, Homburg R, Hickey T, Franks S, Tapanainen J, Balen A, Abbott DH, Diamanti-Kandarakis E, Legro RS. (2011) PCOS Forum: Research in polycystic ovary syndrome - Today and Tomorrow. Clin Endocrinol. (Oxford) 74: 424-433.

Rajkhowa M, Bicknell J, Jones M, Clayton RN. (1994) Insulin sensitivity in women with polycystic ovary syndrome: relationship to hyperandrogenemia. Fertil Steril. 61: 605-612.

Rezvanfar MA, Rezvanfar MA, Ahmadi A, Shojaei-Saadi HA, Baeeri M, Abdollahi M. (2012) Molecular mechanism of a novel selenium based complementary medicine which confers protection against hyperandrogenism induced polycystic ovary. Theriogenology 78: 620-631.

Richards JS, Bogovich K. (1982) Effects of human chorionic gonadotropin and progesterone on follicular development in the immature rat. Endocrinology 111: 1429-1438.

Richmond N (1973) Preparation and properties of a cholesterol oxidase from Nocardia sp. and its application to the enzymatic assay of total cholesterol in serum. Clin Chem. 19: 1350-1356.

Rotterdam ESHRE/ASRM-sponsored PCOS consensus workshop group (2004) Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Human Reprod. 19: 41-47.

Ruiz A, Aguilar R, Tebar AM, Gaytan F, Sanchez-Criado JE. (1996) RU486-treated rats show endocrine and morphological responses to therapies analogous to responses of women with polycystic ovary syndrome treated with similar therapies. Biol Reprod. 55: 1284-1291.

Sanchez-Criado JE, Tebar M, Gaytan F. (1993) Evidence that androgens are involved in atresia and anovulation induced by antiprogesterone RU486 in rats. J Reprod Fertil. 99: 173-179.

Saruc M, Yuceyar H, Ayhan S, Turkel N, Tuzcuoglu I, Can M. (2003) The association of dehydroepiandrosterone, obesity, waist hip ratio and insulin resistance with fatty liver in postmenopausal women-a hyperinsulinemic euglycemic insulin clamp study. Hepatogastroenterology 50: 771-774.

Sasikala SL, Shamila S. (2009) A novel ayurvedic medicine-Ashokarishtam in the treatment of Letrozole induced PCOS in rat. J Cell Tissue Res. 9: 1903-1907.

Shivalingappa H, Satyanaranyan ND, Purohit MG, Sahranabasappa A, Patil SB. (2002) Effect of ethanol extract of Rivea hypocraterifomis on the estrous cycle of the rat. J Ethnopharmacol. 82: 11-17.

Simoni M, Nieschlag E. (1995) FSH in therapy: physiological basis, new preparations and clinical use. Reprod Med Rev 4: 163-177.

Straczkowski M, Dzienis-Straczkowska S, Szelachowska M, Kowalska I, Stepien A, Kinalska I. (2003) Insulin resistance in obese subjects with impaired glucose tolerance. Studies with hyperinsulinemic euglycemic clamp technique. Pol Arch Med Wewn. 109: 359-364.

Strowitzki T, Capp E, Von ECH. (2010) The degree of cycle irregularity correlates with the grade of endocrine and metabolic disorders in PCOS patients. European J Obstet Gynecol Reprod Biol. 149: 178-181.

Taya K, Terranova PF, Greenwald GS. (1981) Acute effects of exogenous progesterone on follicular steroidogenesis in the cyclic rat. Endocrinology 108: 2324-2330.

Teede H, Deeks, A, Moran L (2010) Polycystic ovary syndrome: a complex condition with psychological, reproductive and metabolic manifestations that impacts on health across the lifespan. BMC Med. 8: 41.

Telefo PB, Moundipa PF, Tchana AN, Tchouanguep Dzickotze C, Mbiapo FT. (1998) Effects of an aqueous extract of Aloe buettneri, Justicia insularis, Hibiscus macranthus, Dicliptera verticillata on some physiological and biochemical parameters of reproduction in immature female rats. J Ethnopharmacol. 63: 193-200.

Tietz NW. (1995) Clinical Guide to Laboratory Tests, ed 3, Philadelphia: WB Saunders Company. pp 1-997.

Walters KA, Allan CM, Handelsman DJ. (2012a) Rodent models for human polycystic ovary syndrome. Biol Reprod. 86:149, 1–12.

Walters KA, Middleton LJ, Joseph SR, Hazra R, Jimenez M, Simanainen U, Allan CM, Handelsman DJ. (2012b) Targeted loss of androgen receptor signaling in murine granulosa cells of preantral and antral follicles causes female subfertility. Biol Reprod. 87: 151, 1-11.

Wide L. (1981) Electrophoretic and gel chromatography analyses of follicle stimulating hormone in human serum. Upsala J Med Sci. 86: 249- 258.

Yakubu MT, Akanji MA, Oladiji AT, Olatinwo AO, Adesokan AA, Yakubu MO, Owoyele BV, Sunmonu TO, Ajao MS. (2008) Effect of Cnidoscolous aconitifolius (Miller) I.M. Johnston leaf extract on reproductive hormones of female rats. Iranian J. Reprod Med. 6: 149-155.

Yakubu MT, Ibiyo BO. (2013) Effects of aqueous extract of Cnestis ferruginea (Vahl ex DC) root on the biochemical and clinical parameters of anastrozole-induced polycystic ovarian syndrome rat model. J Endocrinol Reprod. 17: 99-112.

Yakubu MT, Salau AK, Oloyede OB, Akanji MA. (2014) Effect of aqueous leaf extract of Ficus exasperate in alloxan-induced diabetic Wistar rats. Cam J Exp Biol. 10:35-43.


Refbacks

  • There are currently no refbacks.